Skip to main content
Mark Fesler Commented on a Post
  • Saved

Belantamab mafodotin FD: New treatment regimens for multiple myeloma

March is Multiple Myeloma Awareness Month and this is an exciting time due to recently approved therapies for multiple myeloma.

1. Selinexor, an XPO1 inhibitor, was first approved in combination with dexamethasone for penta-refractory patients (refractory to two protease inhibitors, two immunomodulators and an anti-CD38 monoclonal antibody) and recently received a supplementary approval in combination with bortezomib and dexamethasone for second-line or later multiple myeloma.

2. Belantamab mafodotin, an antibody-drug conjugate targeting BCMA, is approved for triple-class exposed patients that have been treated with at least four prior therapies including a protease inhibitor, an immunomodulator and an anti-CD38 monoclonal antibody.

3. Melphalan-flufenamide, a peptide conjugated alkylating drug, was approved for triple-refractory multiple myeloma patients that have been treated with at least four prior therapies.

Which of these regimens will have the greatest impact on your practice? Are there certain groups of patients better suited to a given therapy?


Selinexor FDA label

Belantamab mafodotin FDA label

Melphalan-flufenamide FDA label

  • 3 weeks 3 days
    Most excited about belantamab given ORR and novel mechanism of action. Seems that melphalan-flufenamide would be best suited for those patients who had long remissions from prior cytotoxic therapy. It’s unclear what patients are best suited to selinexor at this point